We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Insulin Resistance and T2D Associated With Gut Microbial Diversity

By LabMedica International staff writers
Posted on 13 Aug 2021
Print article
The MiSeqDx System is the first FDA-regulated, CE-IVD-marked, NGS platform for in vitro diagnostic (IVD) testing (Photo courtesy of Illumina)
The MiSeqDx System is the first FDA-regulated, CE-IVD-marked, NGS platform for in vitro diagnostic (IVD) testing (Photo courtesy of Illumina)
Type 2 diabetes (T2D) is a common complex metabolic disorder. Currently, more than 380 million people live with type 2 diabetes globally, and this number is expected to increase to more than 550 million by 2030.

Differences in gut microbiome composition with T2D status may comprise pathways on how dietary and other environmental factors affect development of insulin resistance and T2D. Patients with T2D have a lower overall α diversity of gut microbiome composition than healthy people.

A multidisciplinary international team of scientists led by those at the Erasmus University Medical Center (Rotterdam, the Netherlands) examined associations of gut microbiome composition with insulin resistance and T2D in a large population-based setting controlling for various sociodemographic and lifestyle factors. The team carried out a cross-sectional analysis included 2,166 participants from two Dutch population-based prospective cohorts.
The investigators used an automated stool DNA isolation kit (Diasorin, Saluggia, Italy) to isolate bacterial DNA. The V3 and V4 hypervariable regions of the bacterial 16S ribosomal RNA gene were amplified and sequenced on the MiSeq platform (Illumina, San Diego, CA, USA). Serum insulin was measured by electrochemiluminescence immunoassay technology. In one study, glucose levels were measured by hydrogen 1 nuclear magnetic resonance, and serum insulin was measured on an architect system (Abbott Laboratories, Lake Forest, IL, USA). Associations among α diversity, β diversity, and taxa with the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and with type 2 diabetes were examined.

The investigators reported that lower microbiome Shannon index and richness were associated with higher HOMA-IR (e.g., Shannon index, −0.06; 95% CI, −0.10 to −0.02), and patients with type 2 diabetes had a lower richness than participants without diabetes (odds ratio [OR], 0.93; 95% CI, 0.88-0.99). The β diversity)was associated with insulin resistance. A total of 12 groups of bacteria were associated with HOMA-IR or type 2 diabetes. There were five taxa whose higher abundance was tied to lower prevalence of T2D:Clostridiaceae 1, Peptostreptococcaceae, Clostridium sensu stricto 1, Intestinibacter, and Romboutsia. There were seven taxa whose greater abundance was associated with lower HOMA-IR including Christensenellaceae and Marvinbryantia.

The authors concluded that higher microbiome α diversity, along with more butyrate-producing gut bacteria, was associated with less T2D and with lower insulin resistance among individuals without diabetes. These findings could help provide insight into the etiology, pathogenesis, and treatment of T2D. The study was published on July 29, 2021 in the journal JAMA Network Open.

Related Links:

Erasmus University Medical Center
Abbott Laboratories

Gold Supplier
Rapid PCR Diagnostic System
Accula System
Next-Generation Sequencing Platform
Clear Dx
Silver Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
Clinical Chemistry Analyzer
Mispa CXL Pro

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.